Understanding Biosimilar Medications: Key Insights and Uses
This article provides an in-depth look at biosimilar medicines, especially their role in psoriasis treatment. It explains the differences between biologics and biosimilars, safety considerations, and available FDA-approved drugs. Additionally, it highlights potential side effects and emphasizes the importance of professional medical guidance for these therapies. Understanding biosimilars can help patients and healthcare providers make informed decisions about psoriasis management and future medical advances.
Psoriasis remains a significant health concern in the United States, manifesting in various forms such as plaque, inverse, guttate, and erythrodermic psoriasis. The condition often affects nails and other body parts. Fortunately, some biosimilar treatments are approved for managing this disease, offering new options for patients.
How Do Biologics and Biosimilars Differ?
Biologic therapies target specific immune system components, aiming for precision treatment, while biosimilars are close copies of biologics but have distinct safety profiles.
Furthermore, biosimilars share similar mechanisms and dosing regimens with biologic drugs.
Who Can Use Biosimilars?
Biosimilars are typically recommended for patients with severe psoriasis. They may also be used in individuals with active infections or compromised immune systems. The effects on infants, fetuses, or pregnant women are not fully understood, and such medications are only prescribed during pregnancy when necessary.
Approved Biosimilars for Psoriasis
Reflexes and Inflectra, similar to Remicade
Erelzi, comparable to Etanercept
Adalimumab-adbm and Adalimumab-atto, both similar to Adalimumab
Potential Side Effects
Like all treatments, biosimilars can cause adverse effects, which may include:
Headache
Skin redness, swelling, and warmth
Upper respiratory infections
Flu-like symptoms such as fever and chills
Sweating
Chest or nasal congestion
Shortness of breath
Abdominal pain
Injection reactions
Researchers are exploring biosimilars' potential for treating other serious illnesses. However, these treatments should only be administered under professional medical supervision at reputable centers like Mayo Clinic or UCSF, not through over-the-counter purchases.
